Frontal lobe N-acetylaspartate correlates with psychopathology in schizophrenia: A proton magnetic resonance spectroscopy study

Schizophrenia Research

Volumn 64, Issue 1, 2003, Pages 63-71

  Sigmundsson, Thordur ^a,b   Maier, Michael ^c   Toone, Brian K ^a   Williams, Steven C R ^a   Simmons, Andrew ^a   Greenwood, Kathryn ^a   Ron, Maria A ^d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Frontal lobe; N acetylaspartate (NAA); Proton magnetic resonance spectroscopy (1H MRS); Psychopathology; Schizophrenia

Indexed keywords

BIOLOGICAL MARKER; CHOLINE; CREATINE; CREATINE PHOSPHATE; N ACETYLASPARTIC ACID;

ADULT; AMINO ACID ANALYSIS; AMINO ACID BRAIN LEVEL; ARTICLE; BRAIN LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FRONTAL LOBE; HUMAN; MALE; MENTAL DISEASE; METABOLITE; NEGATIVE SYNDROME; POSITIVE SYNDROME; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; SCHIZOPHRENIA; SOCIAL INTERACTION; SYMPTOM;

EID: 0141679200     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(02)00533-9     Document Type: Article

References (59)

1. Akbarian S., Bunney W.E. Jr., Potkin S.G., Wigal S.B., Hagman J.O., Sandman C.A., Jones E.G. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diphorase cells in frontal lobe of schizophrenic implies disturbance of cortical development. Arch. Gen. Psychiatry. 50:1993;169-177.
2. Andreasen N.C., Ehrhardt J.C., Swayze V.W. II, Alliger R.J., Yuh W.T., Cohen G., Ziebell S. Magnetic resonance imaging of the brain in schizophrenia. The pathophysiologic significance of structural abnormalities. Arch. Gen. Psychiatry. 47:1990;35-44.
3. Andreasen N.C., Rezai K., Alliger R., Swayze V.W. II, Flaum M., Kirchner P., Cohen G., O'Leary D.S. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch. Gen. Psychiatry. 49:1992;943-958.
4. Andreasen N.C., Flashman L., Flaum M., Arndt S., Swayze V. II, O'Leary D.S., Ehrhardt J.C., Yuh W.T. Regional brain abnormalities in schizophrenia measured with magnetic resonance imaging. JAMA. 272:1994;1763-1769.
5. Arnold D.L. Reversible reduction of NAA after acute central nervous system damage. Book Abstr. - Soc. Magn. Reson. Med. 1:1992;643.
6. Barker P.B., Soher B.J., Blackband S.J., Chatham J.C., Mathews V.P., Bryan R.N. Quantitation of proton NMR spectra of the human brain using tissue water as an internal concentration reference. NMR Biomed. 6:1993;89-94.
7. Benes F.M. Is there neuronal loss in schizophrenia? Int. Rev. Psychiatry. 9:1997;429-436.
8. Bertolino A., Nawroz S., Mattay V.S., Barnett A.S., Duyn J.H., Moonen C.T., Frank J.A., Tedeschi G., Weinberger D.R. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am. J. Psychiatry. 153:1996;1554-1563.
9. 1H-NMR spectroscopic studies of brain. Neurosci. Biobehav. Rev. 13:1989;23-31.
10. Breier A., Buchanan R.W., Elkashef A., Munson R.C., Kirkpatrick B., Gellad F. Brain morphology and schizophrenia. A magnetic resonance imaging study of limbic, prefrontal cortex, and caudate. Arch. Gen. Psychiatry. 49:1992;921-926.
11. Brenner R.E., Beech J.S., Williams S.C.R., Bell J.D., McDonald W.I. Reversibility of the reduction of NAA in diabetic ketoacidosis. Book Abstr. - Soc. Magn. Reson. Med. 3:1993;1559.
12. Bruhn H., Frahm J., Gyngell M.L., Merboldt K.D., Hanicke W., Sauter R. Cerebral metabolism in man after acute stroke: new observations using localized proton NMR spectroscopy. Magn. Reson. Med. 9:1989;126-131.
13. 1H-magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia: clinical, neurodevelopmental, and cognitive correlates. Biol. Psychiatry. 36:1994;792-800.
14. Callicott J.H., Bertolino A., Egan M.F., Mattay V.S., Langheim F.J.P., Weinberger D.R. Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia. Am. J. Psych. 157:2000;1646-1651.
15. Carpenter W.T. Jr., Heinrichs D.W., Wagman A.M. Deficit and nondeficit forms of schizophrenia: the concept. Am. J. Psychiatry. 145:1988;578-583.
16. Choe B.Y., Suh T.S., Shinn K.S., Lee C.W., Lee C., Paik I.H. Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. Invest. Radiol. 31:1996;345-352.
17. 1H-MRS using water as an internal standard. Magn. Reson. Imaging. 11:1993;107-118.
18. Davie C.A., Hawkins C.P., Barker G.J., Brennan A., Tofts P.S., Miller D.H., McDonald W.I. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain. 117(Pt 1):1994;49-58.
19. Deicken R.F., Zhou L., Corwin F., Vinogradov S., Weiner M.W. Decreased left frontal lobe N-acetylaspartate in schizophrenia. Am. J. Psychiatry. 154:1997;688-690.
20. 1H MRS) in schizophrenia: Investigation of the right and left hippocampus, thalamus, and prefrontal cortex. Schizophr. Bull. 28:2002;329-339.
21. De Stefano N., Matthews P.M., Antel J.P., Preul M., Francis G., Arnold D.L. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann. Neurol. 38:1995;901-909.
22. Elliott R., Sahakian B.J. The neuropsychology of schizophrenia: relations with clinical and neurobiological dimensions. Psychol. Med. 25:1995;581-594.
23. Endicott J., Spitzer R.L., Fleiss J.L., Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch. Gen. Psychiatry. 33:1976;766-771.
24. Foong J., Maier M., Barker G., Miller D.H., Ron M.A. Use of magnetisation transfer imaging in vivo to investigate the neuropathology in schizophrenia. Schizophr. Res. 29:1998;80.
25. Frahm J., Bruhn H., Gyngell M.L., Merboldt K.D., Hanicke W., Sauter R. Localized proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites. Magn. Reson. Med. 11:1989;47-63.
26. Franzen G., Ingvar D.H. Absence of activation in frontal structures during psychological testing of chronic schizophrenics. J. Neurol. Neurosurg. Psychiatry. 38:1975;1027-1032.
27. Fukuzako H., Takeuchi K., Hokazono Y., Fukuzako T., Yamada K., Hashiguchi T., Obo Y., Ueyama K., Takigawa M., Fujimoto T. Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: preliminary report. Psychiatry Res. 61:1995;193-200.
28. Gill S.S., Thomas D.G., Van Bruggen N., Gadian D.G., Peden C.J., Bell J.D., Cox I.J., Menon D.K., Iles R.A., Bryant D.J. Proton MR spectroscopy of intracranial tumours: in vivo and in vitro studies. J. Comput. Assist. Tomogr. 14:1990;497-504.
29. Gold J.M., Weinberger D.R. Cognitive deficits and the neurobiology of schizophrenia. Curr. Opin. Neurobiol. 5:1995;225-230.
30. Gur R.C., Gur R.E. Hypofrontality in schizophrenia: RIP. Lancet. 345:1995;1383-1384.
31. Harrison P.J. The neuropathological effects of antipsychotic drugs. Schizophr. Res. 40:1999;87-99.
32. Hennig J., Pfister H., Ernst T., Ott D. Direct absolute quantification of metabolites in the human brain with in vivo localized proton spectroscopy. NMR Biomed. 5:1992;193-199.
33. 1H NMR spectroscopy. Neurology. 43:1993;2689-2695.
34. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13:1987;261-276.
35. Kirkpatrick B., Buchanan R.W., McKenney P.D., Alphs L.D., Carpenter W.T. Jr. The Schedule for the Deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 30:1989;119-123.
36. Koller K.J., Zaczek R., Coyle J.T. N-acetyl-aspartyl-glutamate: regional levels in rat brain and the effects of brain lesions as determined by a new HPLC method. J. Neurochem. 43:1984;1136-1142.
37. Kreis R., Ernst T., Ross B.D. Development of the human brain: in vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy. Magn. Reson. Med. 30:1993;424-437.
38. Levin S. Frontal lobe dysfunctions in schizophrenia: II. Impairments of psychological and brain functions. J. Psychiatr. Res. 18:1984;57-72.
39. MacKay S., Ezekiel F., Di Sclafani V., Meyerhoff D.J., Gerson J., Norman D., Fein G., Weiner M.W. Alzheimer disease and subcortical ischemic vascular dementia: evaluation by combining MR imaging segmentation and H-1 MR spectroscopic imaging. Radiology. 198:1996;537-545.
40. Maier M. In vivo magnetic resonance spectroscopy. Applications in psychiatry. Br. J. Psychiatry. 167:1995;299-306.
41. Maier M., Ron M.A., Barker G.J., Tofts P.S. Proton magnetic resonance spectroscopy: an in vivo method of estimating hippocampal neuronal depletion in schizophrenia. Psychol. Med. 25:1996;1201-1209.
42. Manton D.J., Lowry M., Blackband S.J., Horsman A. Determination of proton metabolite concentrations and relaxation parameters in normal human brain and intracranial tumours. NMR Biomed. 8:1995;104-112.
43. Miller B.L. A review of chemical issues in 1H NMR spectroscopy. N-acetyl-L-aspartate, creatine and choline. NMR Biomed. 4:1991;47-52.
44. Morris R.G., Rushe T., Woodruffe P.W., Murray R.M. Problem solving in schizophrenia: a specific deficit in planning ability. Schizophr. Res. 14:1995;235-246.
45. Nelson H.E., Willison J. National Adult Reading Test. 1991;NFER-Nelson, Windsor.
46. Petroff O.A. Biological 1H NMR spectroscopy. Comp. Biochem. Physiol., B. 90:1988;249-260.
47. Ross B., Michaelis T. Clinical applications of magnetic resonance spectroscopy. Magn. Reson. Q. 10:1994;191-247.
48. Saykin A.J., Gur R.C., Gur R.E., Mozley P.D., Mozley L.H., Resnick S.M., Kester D.B., Stafiniak P. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch. Gen. Psychiatry. 48:1991;618-624.
49. Schlaepfer T.E., Harris G.J., Tien A.Y., Peng L.W., Lee S., Federman E.B., Chase G.A., Barta P.E., Pearlson G.D. Decreased regional cortical gray matter volume in schizophrenia. Am. J. Psychiatry. 151:1994;842-848.
50. Schonell F. Backwardness in the Basic Subjects. 1942;Oliver and Boyd, London.
51. Selemon L.D., Rajkowska G., Goldman-Rakic P.S. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch. Gen. Psychiatry. 52:1995;805-818.
52. Soher B.J., Hurd R.E., Sailasuta N., Barker P.B. Quantitation of automated single-voxel proton MRS using cerebral water as an internal reference. Magn. Reson. Med. 36:1996;335-339.
53. Spence S.A., Hirsch S.R., Brooks D.J., Grasby P.M. Prefrontal cortex activity in people with schizophrenia and control subjects. Evidence from positron emission tomography for remission of 'hypofrontality' with recovery from acute schizophrenia. Br. J. Psychiatry. 172:1998;316-323.
54. Stanley J.A., Williamson P.C., Drost D.J., Rylett R.J., Carr T.J., Malla A., Thompson R.T. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophr. Bull. 22:1996;597-609.
55. Tsai G., Coyle J.T. N-acetylaspartate in neuropsychiatric disorders. Prog. Neurobiol. 46:1995;531-540.
56. Turetsky B., Cowell P.E., Gur R.C., Grossman R.I., Shtasel D.L., Gur R.E. Frontal and temporal lobe brain volumes in schizophrenia. Relationship to symptoms and clinical subtype. Arch. Gen. Psychiatry. 52:1995;1061-1070.
57. Vion-Dury J., Meyerhoff D.J., Cozzone P.J., Weiner M.W. What might be the impact on neurology of the analysis of brain metabolism by in vivo magnetic resonance spectroscopy? J. Neurol. 241:1994;354-371.
58. Weinberger D.R. Schizophrenia and the frontal lobe. Trends Neurosci. 11:1988;367-370.
59. Weinberger D.R., Berman K.F., Zec R.F. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia: I. Regional cerebral blood flow evidence. Arch. Gen. Psychiatry. 43:1986;114-124.